Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Anacaulase→

Anacaulase Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
Not verified
Molecular formula
Not applicable (enzyme mixture)
Molecular weight
23000 g/mol
Drug class
Concentrate of proteolytic enzymes enriched in bromelaintopical enzymatic debriding biologic
Mechanism of action
A mixture of proteolytic enzymes extracted from pineapple stem dissolves burn-wound eschar. The individual enzyme components responsible for this effect have not been identified.
Indications / reported uses
  • Removal of eschar in adults and paediatric patients with deep partial-thickness and/or full-thickness thermal burns; application is limited to trained healthcare professionals and specialised burn-care settings

Sources: EMA EPAR — NexoBrid · US FDA/DailyMed — NEXOBRID prescribing information · FDA orphan-drug approval record · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Anacaulase Environmental Risk Assessment (ERA) (the Anacaulase ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.